Professoressa Ordinaria – Dipartimento di Medicina Clinica e Sperimentale | Tel.: 050 993488 – Email: sara.galimberti@unipi.it<\/p>\n","protected":false},"template":"","meta":{"unipi-persone-chiave":"183","unipi-persone-nome":"Sara","unipi-persone-cognome":"Galimberti","unipi-persone-email":"sara.galimberti@unipi.it","unipi-persone-cv":"From May 2022 to today: Full Professor in Hematology - University of Pisa, Italy.
\r\n
\r\nFrom November 2021 to today: Chief of the Hematology Division, Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa
\r\n
\r\nFrom March 2018 to today: Director of the School of specialization in Hematology \u2013 University of Pisa, Italy
\r\n
\r\nFrom November 2017 to May 2022: Associate Professor in Hematology, University of Pisa, Italy
\r\n
\r\nFrom June 2001 to November 2017: Researcher in Hematology, University of Pisa, Italy
\r\n
\r\nFrom December 2000 to June 2001: Physician at the Hematology AOUP
\r\nNovember 2024- July 2025: Master II level in Health Management (ManSan) \u2013 Faculty of Economics \u2013 University of Pisa, Pisa, Italy.
\r\n
\r\nMarch 2025 \u2013 October 2025: Corso di Formazione in MAnagement delle TErapie CaR-T \u201cMATER II\u201d at the LUIC Business School, Varese, Italy
\r\n
\r\n
\r\nOctober 1999: Specialization in Hematology, University of Pisa, Italy.
\r\n
\r\nDecember 1996: PhD in Experimental Medicine, Scuola Superiore di Studi Universitari e Perfezionamento \u201cS. Anna\u201d, Pisa.
\r\n
\r\nOctober 1992: Degree in Medicine and Surgery, University of Pisa and Scuola Superiore di Studi Universitari e Perfezionamento \u201cS. Anna\u201d, Pisa.
\r\nAbout clinical expertise, Prof. Galimberti has been and is P.I. and co-P.I. in several phase-I, phase-II, phase-III, and phase-IV clinical trials for acute leukemias, myeloma, lymphomas, and chronic myeloproliferative and lymphoproliferative diseases. In the last 5 years, Prof. Galimberti has been P.I. in 23 clinical trials and sub investigator in 8 trials. In July 2025, 38 clinical trials are ongoing, 13 of them no-profit (including those sponsored by the Fondazione Italiana infomi) and GIMEMA networks at the Hematology of Pisa.
\r\nFocused on CAR-T, Prof. Galimberti is the leader for the Pisa University of the project \u201cHLS-TA PNC-E3-23683269 FINANCED UNDER THE NATIONAL COMPLEMENTARY PLAN \u201cINNOVATIVE HEALTH ECOSYSTEM\u201d (P.I. Prof. Locatelli, Rome) where Pisa is involved in the monitoring of CAR-T by immunophenotyping and molecular biology techniques, in addition to the advanced ultrasonography. In the last 3 years, at the AOUP 66 patients affected by lymphoma, leukemia, and myeloma received autologous CAR-T, and 3 patients received allogeneic CAR-T against EBV-related lymphomas. Pisa is the hub center for the North-West part of Tuscany that refers patients to the academic center for advanced therapies, immunotherapies, and transplants.
\r\nProf. Galimberti\u2019s lab is responsible for the MRD monitoring in the FIL and participated with other 3 labs to the harmonization process of the MRD assessment in MM by NGS.
\r\nThe Pisa lab is also member of the European net for MRD assessment and every year completes the UK NEQAS quality controls. Prof. Galimberti is one of the members of the GIMEMA CML LABNET scientific board, that designs the protocols for MRD tests in CML. The more than 350 articles published by Prof. Galimberti demonstrate her ability to conduct clinical trials, both profit and no-profit. The Pisa clinical trial office at the University of Pisa and at the AOUP support the hematological protocols center where 2 data mangers and one trial nurse work.
\r\n
\r\nAlready during the period of the postgraduate course, Prof. Galimberti attended the molecular laboratory and the Hematology department of the University of Pisa, in Italy. From November to December 1993 and later in February 2005 she attended the laboratory of Prof. Giuseppe Saglio (Orbassano, Turin). Since then, the research activity has always focused mainly on bio-molecular aspects underlying the pathogenesis of the main hematological diseases, in particular the mechanisms of chemoresistance, the identification of molecular prognostic markers responsible for treatment failure or GVHD. Interest has also been devoted to the study of signal transduction mechanisms of new drugs, such as proteasome inhibitors, histone deacetylase inhibitors and TKIs. Prof. Galimberti is scientific director of the Molecular Biology Labo","unipi-persone-link-esterno-cv":"","unipi-persone-modalita-ricevimento":"previo appuntamento per e.mail all'indirizzo: sara.galimberti@unipi.it","unipi-persone-luogo-ricevimento":"","unipi-persone-ore-ricevimento":"","unipi-persone-telefono":"050 993488 ","unipi-persone-sitoweb":"http:\/\/www.med.unipi.it\/index.php?option=com_content&view=article&id=557&Itemid=732&lang=it","unipi-persone-cariche":"